Insulin, Glucagon, & the Incretin Defect in Type 2 Diabetes (6:48)

In this video, Dr David D’Alessio discusses the importance of islet dysfunction in type 2 diabetes, reviews the incretin effect, and describes the role of glucagon-like peptide-1 (GLP-1) in type 2 diabetes.

0214-00020129-1
0214-00020129-1
Play
Pause
Skip
Volume
Chapters
Transcript
References
Subtitles
Fullscreen

Insulin, Glucagon, & the Incretin Defect in Type 2 Diabetes (6:48)

Chapters
Transcript
References

In this video, Dr David D’Alessio discusses the importance of islet dysfunction in type 2 diabetes, reviews the incretin effect, and describes the role of glucagon-like peptide-1 (GLP-1) in type 2 diabetes.

Return to overview

Transcripts

Return to overview

References

1. Müller WA, Faloona GR, Aguilar-Parada E, Unger RH. 
    Abnormal alpha-cell function in diabetes. Response to
    carbohydrate and protein ingestion. N Engl J Med.
    1970;283(3):109-115.

2. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr.
    Diminished B cell secretory capacity in patients with
    noninsulin-dependent diabetes mellitus. J Clin Invest.
    1984;74(4):1318-1328.

3. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA.
    Lack of suppression of glucagon contributes to
    postprandial hyperglycemia in subjects with type 2
    diabetes mellitus. J Clin Endocrinol Metab. 2000;85(11):
    4053-4059.

4. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and
    GIP. Gastroenterology. 2007;132(6):2131-2157.

5. Vilsbøll T, Krarup T, Sonne J, et al. Incretin secretion in
    relation to meal size and body weight in healthy subjects
    and people with type 1 and type 2 diabetes mellitus.
    J Clin Endocrinol Metab. 2003;88(6):2706-2713.

6. Vilsbøll T, Krarup T, Madsbad S, Holst JJ. Defective
    amplification of the late phase insulin response to
    glucose by GIP in obese type II diabetic patients.
    Diabetologia. 2002;45(8):1111-1119.

7. Kjems LL, Holst JJ, Vølund A, Madsbad S. The influence of
    GLP-1 on glucose-stimulated insulin secretion: effects on
    beta-cell sensitivity in type 2 and nondiabetic subjects.
    Diabetes. 2003;52(2):380-386.

8. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B,
    Creutzfeldt W. Normalization of fasting hyperglycaemia
    by exogenous glucagon-like peptide 1 (7-36 amide) in
    type 2 (non-insulin-dependent) diabetic patients. 
    Diabetologia. 1993;36(8):741-744.

9. Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Reduced
    incretin effect in type 2 (non-insulin-dependent) diabetes.
    Diabetologia. 1986;29(1):46-52.